| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 2071979 | Advanced Drug Delivery Reviews | 2006 | 14 Pages |
Abstract
The first generation of human cancer vaccines has been tested in phase III clinical trials, but only a few of these have demonstrated sufficient efficacy to be licensed for clinical use. This article reviews some of the mechanisms that could contribute to these limited clinical responses, and highlights the challenges faced for development of future vaccines.
Related Topics
Life Sciences
Biochemistry, Genetics and Molecular Biology
Biotechnology
Authors
Z. Tabi, S. Man,